Search Results - "McDonald, Mirna"

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
  2. 2

    Reslizumab as add-on therapy in patients with refractory asthma by Virchow, J Christian, McDonald, Mirna, Garin, Margaret, Korn, Stephanie

    Published in BMJ open respiratory research (08-04-2020)
    “…Approximately 5%–10% of patients with asthma are believed to suffer from severe disease.4 Patients with severe asthma typically require ongoing maintenance…”
    Get full text
    Journal Article
  3. 3

    Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects by Green, Justin A., Patel, Apurva K., Patel, Bela R., Hussaini, Azra, Harrell, Emma J., McDonald, Mirna J., Carter, Nick, Mohamed, Khadeeja, Duparc, Stephan, Miller, Ann K.

    Published in Journal of clinical pharmacology (01-09-2014)
    “…Tafenoquine is being developed for relapse prevention in Plasmodium vivax malaria. This Phase I, single‐blind, randomized, placebo‐ and active‐controlled…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Early decreases in blood eosinophil levels with reslizumab by Chanez, Pascal, McDonald, Mirna, Garin, Margaret, Murphy, Kevin

    Published in Journal of allergy and clinical immunology (01-04-2019)
    “…Detailed description of the study designs has been reported previously.5 In brief, eligible patients were aged 12 to 75 years with inadequately controlled…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8

    Reslizumab improves FVC and FEF25%-75% in severe eosinophilic asthma: results from a pooled analysis by Carr, Warner W., McDonald, Mirna, Meizlik, Paige

    Published in Journal of allergy and clinical immunology (01-02-2018)
    “…Rationale IV reslizumab (RES), a humanized anti-interleukin-5 monoclonal antibody, demonstrated significant improvement in FEV1 at 52 weeks in patients aged…”
    Get full text
    Journal Article
  9. 9

    Baseline Characteristics Associated with Quartiles of Reslizumab Effect: Pooled Analysis Of Two Phase 3 Studies by Chipps, Bradley E., McDonald, Mirna, Garin, Margaret

    Published in Journal of allergy and clinical immunology (01-02-2018)
    “…Rationale IV reslizumab (RES), a humanized anti-interleukin-5 monoclonal antibody, significantly reduced risk of asthma exacerbations and improved asthma…”
    Get full text
    Journal Article
  10. 10

    Improvements In Individual Asthma Control Questionnaire (ACQ-5) Questions With Reslizumab In Patients With Inadequately Controlled Asthma and Elevated Blood Eosinophils: Pooled Analysis of Two Phase 3 Trials by Korenblat, Phillip E., McDonald, Mirna, Garin, Margaret

    Published in Journal of allergy and clinical immunology (01-02-2018)
    “…Results Compared to PBO (n=475), RES (n=477) resulted in improvement in Q1 (nighttime awakenings [NA]) by -0.3, Q2 (morning symptoms [MS]) by -0.5, Q3…”
    Get full text
    Journal Article
  11. 11

    Association Between Asthma Exacerbations and Lung Function With Reslizumab Treatment In Patients With Uncontrolled Eosinophilic Asthma: Pooled Analysis of Two Phase 3 Trials by Fahrenholz, John M., McDonald, Mirna, Garin, Margaret

    Published in Journal of allergy and clinical immunology (01-02-2018)
    “…Rationale Reslizumab (RES), a humanized anti-interleukin-5 monoclonal antibody, significantly reduced the risk of clinical asthma exacerbation (CAE) in…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials by Halker Singh, Rashmi B, Aycardi, Ernesto, Bigal, Marcelo E, Loupe, Pippa S, McDonald, Mirna, Dodick, David W

    Published in Cephalalgia (01-01-2019)
    “…In phase 2 and 3 studies, fremanezumab, a monoclonal CGRP antibody, was an effective preventive treatment for high-frequency episodic migraine (HFEM) and…”
    Get more information
    Journal Article
  14. 14

    Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials by Virchow, J. Christian, Katial, Rohit, Brusselle, Guy G., Shalit, Yael, Garin, Margaret, McDonald, Mirna, Castro, Mario

    “…Intravenous reslizumab, a monoclonal IL-5 antibody, is approved for treating severe asthma with eosinophilia. Limited structured information is available on…”
    Get full text
    Journal Article
  15. 15

    Efficacy of Reslizumab in Asthma Patients with Aspirin Sensitivity and Elevated Blood Eosinophils by Katial, Rohit, Hoyte, Flavia, Germinaro, Matthew, MD, McDonald, Mirna

    Published in Journal of allergy and clinical immunology (01-02-2017)
    “…Conclusions Patients with inadequately controlled asthma, elevated blood eosinophils, and ASA sensitivity (±CRSwNP) received significant therapeutic benefit,…”
    Get full text
    Journal Article
  16. 16